Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade · PMID 42321916
View analysis →A grade · PMID 42372741
View analysis →A grade · PMID 42382416
View analysis →A grade · PMID 42150584
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 38.2; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 83.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 83.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 18.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 38.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 38.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 37.8; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 50.1; sample size: 20.0; recency: 90.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.0/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 45.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.0/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.0/100. Study design: 60.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.0/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 63.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 100.0; abstract quality: 20.0.
